66 Biggest Movers From Yesterday Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. Benzinga · May 3, 2022
Union Pacific Whale Trades For May 02 A whale with a lot of money to spend has taken a noticeably bullish stance on Union Pacific. Looking at options history for Union Pacific (NYSE:UNP) we detected 33 strange trades. Benzinga · May 2, 2022
What To Know About Raymond James's Upgrade of Arthur J. Gallagher Raymond James upgraded its rating of Arthur J. Gallagher (NYSE:AJG) to Strong Buy with a price target of $195.00, changing its price target from $185.00 to $195.00. Shares of Arthur J. Gallagher are trading down 1.07% over the last 24 hours, at $166.68 per share. Benzinga · May 2, 2022
Why These Analysts Cut Price Target On Teleflex RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance. Benzinga · Apr 29, 2022
Why These Analysts Are Bullish On Gilead's Q1 Earnings RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,… Benzinga · Apr 29, 2022
Apple Analysts See Production Issues As Transitory, Recommend Buying On Weakness Following Q2 Results Apple Inc (NASDAQ: AAPL) reported better-than-expected second-quarter earnings and revenues. Benzinga · Apr 29, 2022
'Long Road Of Rebuilding Begins': PayPal Analysts React To Mixed Q1 Earnings Report Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance. Benzinga · Apr 28, 2022
Improved Costs, Reels Growth, Attractive Multiples: What 6 Analysts Are Saying About Meta Platforms Post Earnings Shares of social media and metaverse company Meta Platforms Inc (NASDAQ: FB) traded higher Wednesday after market close. The move came after the company reported first-quarter financial results. Here are the key takeaways from the earnings report from analysts. Benzinga · Apr 28, 2022
Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current… Benzinga · Apr 28, 2022
Occidental Petroleum Whale Trades For April 28 Someone with a lot of money to spend has taken a bearish stance on Occidental Petroleum (NYSE:OXY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Apr 28, 2022
Chipotle Can Navigate Food Cost Concerns, Menu Price Increases: 4 Analysts React To Earnings Report Rising food costs, menu price increases and store growth were the big topics highlighted by analysts who cover restaurant company Chipotle Mexican Grill, Inc. (NYSE: CMG). Here are the key analyst takeaways. Benzinga · Apr 27, 2022
Raymond James Maintains Strong Buy Rating for Mohawk Industries: Here's What You Need To Know Raymond James has decided to maintain its Strong Buy rating of Mohawk Industries (NYSE:MHK) and lower its price target from $220.00 to $190.00. Shares of Mohawk Industries are trading up 0.59% over the last 24 hours, at $125.44 per share. Benzinga · Apr 27, 2022
Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's… Benzinga · Apr 27, 2022
Benzinga · Apr 26, 2022 Analysts Share Their View On Activision Blizzard Post Q1 Performance Analysts offered their views on Activision Blizzard, Inc (NASDAQ:ATVI) post Q1 FY22 results. Raymond James saw ATVI's Q1 results significantly below expectations, driven by continued weakness in Call of Duty and a low ebb of content in Blizzard. It continued to see sizable headwinds for Call of Duty through the rest of the year until the anticipated release…
Benzinga · Apr 26, 2022 Check Out What Whales Are Doing With JNJ Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · Apr 25, 2022 Raymond James Lists Marvell's Sources Of Growth, Profitability Leading To Upgrade Two analysts re-rated Marvell Technology Inc (NASDAQ: MRVL) today.
Benzinga · Apr 25, 2022 Here's Why Raymond James Sees 75.4% Upside In AMD; Upgrades To Strong Buy Raymond James analyst Chris Caso upgraded Advanced Micro Devices Inc (NASDAQ:AMD) to Strong Buy from Outperform with a $160 price target. The price target implies a 75.4% upside. As Caso became more concerned about cycle risks, given the potential for slowing consumer demand and elevated inventory levels at customers, he favored those semi companies with…
Benzinga · Apr 25, 2022 Why AMD Shares Are Trading Higher Today Advanced Micro Devices, Inc. (NASDAQ: AMD) shares are trading higher Monday following positive analyst coverage from Raymond James. Raymond James analyst Chris Caso upgraded the stock from Outperform to Strong Buy and announced a $160 price target.
Benzinga · Apr 22, 2022 Analysts Think Intuitive Surgical Painted 'Cautious Picture' For Procedure Guidance Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ:ISRG) sounded cautious on U.S. capital placements, given rising interest rates and inflationary pressure at hospitals. "We think this commentary was partly driven by the need to recalibrate Street models for fewer trade-ins as the number of legacy Si systems declines. Overall,…
Benzinga · Apr 21, 2022 These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.
Benzinga · Apr 21, 2022 Analysts Bump Up CSX Price Target Post Q1 Results CSX Corp's (NASDAQ:CSX) price target has been raised by two analysts post Q1 results. Raymond James analyst Patrick Tyler Brown raised CSX’s price target to $40 (an upside of 10%) from $39 while maintaining the Outperform rating on the shares. The analyst states that CSX continues to execute its PSR initiatives to drive operational improvement,…
Benzinga · Apr 21, 2022 What Does Raymond James, Wells Fargo Have To Say On Abbott's Q1 Earnings Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8%
Benzinga · Apr 20, 2022 Johnson & Johnson Whale Trades For April 20 A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.